LONDON – Forbion has faced down COVID-19 to reach the first close of €185 million (US$208 million) for a new growth opportunities fund, which will be dedicated to late-stage investments in companies with mature assets.
Shanghai-based Fosun Kite Biotechnology Co. Ltd. secured another $20 million investment from Shanghai Fosun Pharmaceutical (Group) Co. Ltd. and Kite Pharma Inc., which each contributed $10 million. The fund will support further clinical trials and manufacturing of its CAR T candidates, including FKC-876, which looks likely to become the first CAR T therapy approved in China.
LONDON – Varmx BV is poised to demonstrate its modified recombinant factor X acts a universal antidote to reverse the effects of direct oral anticoagulants in patients suffering severe spontaneous bleeding or needing emergency surgery, after closing a €32 million (US$36.1 million) series B round.
DUBLIN – Osivax SAS has assembled a public funding package of more than €32 million (US$36.3 million) to pursue ongoing clinical development of its universal flu vaccine and to take forward a coronavirus vaccine program based on a similar approach, involving vaccine-like particle (VLP) technology.
Velosbio Inc., a San Diego-based company developing cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), has raised $137 million in series B financing to support development of its lead antibody-drug conjugate (ADC), VLS-101, and continued expansion of its pipeline.
DUBLIN – Gesynta Pharma AB raised SEK190 million (US$20.6 million) in new funding to move GS-248, a selective inhibitor of microsomal prostaglandin E synthase-1 (mPGES-1), into a phase IIa trial in systemic sclerosis. The study is due to get underway toward the year end. “It’s going to be in the second half of the fourth quarter,” said Patric Stenberg, CEO of Lund, Sweden-based Gesynta.
HONG KONG – SK Biopharmaceuticals Co Ltd.’s shares are still basking in the afterglow of a successful entrance on the Korea Exchange, which raised ?959.30 billion (US$799 million).
RSS
